Tong Ren Tang Technologies Co Ltd (1666) Fair Value & Analysis
Healthcare · HK · Market cap HK$4.1B
Fair value as of: Aug 13, 2026
From 26 valuation models · updated 6 days ago
Fair value updated Aug 13, 2026, revised from HK$7.91 to HK$7.92 (+0.1%) since Aug 12, 2026. Share price −8.4% over the past month.
A solid business, screening 143% undervalued on our models.
What matters now
- The price is below even our cautious bear case (HK$5.94). The market is more pessimistic than our downside scenario.
- Solid quality (67/100) at a price below fair value, the discount is the argument here, not the business quality.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range HK$3.13 – HK$7.58 · fair‑value band HK$5.94 – HK$9.90 · the HK$3.26 price screens below the HK$7.92 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Tong Ren Tang Technologies Co Ltd (1666) currently trades at HK$3.26, while our model-based Fair Value estimate is HK$7.92, implying the stock looks roughly 142.9% undervalued today. The Quality Score stands at 67/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, Tong Ren Tang Technologies Co Ltd generated revenue of HK$6.5B at a net margin of 6.1%. Revenue declined 14.5% year over year. It earns a return on equity of 6.5%. The balance sheet holds a net cash position of HK$2.5B. Fundamentals as of Aug 13, 2026
Our scenario range runs from HK$5.94 (bear case) to HK$9.90 (bull case); at HK$3.26, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 37% below its 52-week high and 6% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -20% fair-value upside, at 143%, 1666 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: DCF Models (HK$15.89) versus Dividend Discount (HK$2.70). Highest evidence: Growth DCF (80).
Notify me when 1666 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 68 · Market factors (momentum, volatility) 34
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Tong Ren Tang Technologies Co. Ltd., together with its subsidiaries, produces and distributes Chinese medicine products in Mainland China and Hong Kong. It operates through three segments: The Company; Tong Ren Tang Chinese Medicine; and Others.
Full company description
Tong Ren Tang Technologies Co. Ltd., together with its subsidiaries, produces and distributes Chinese medicine products in Mainland China and Hong Kong. It operates through three segments: The Company; Tong Ren Tang Chinese Medicine; and Others. The company develops, cultivates, processes, and purchases Chinese medicinal raw materials; retails and wholesales Chinese medicine products and healthcare products. It also offers ointments, healthcare products, tea drinks, food, foot care products, biological products, western medicine, and cosmetics. In addition, it provides medical research and development; advertisement; and Chinese medical consultations and treatments. Further, the company produces and processes biochemical products; extracts and processes plants; and offers medical services. Tong Ren Tang Technologies Co. Ltd. was founded in 1669 and is based in Beijing, the People's Republic of China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Tong Ren Tang Technologies Co Ltd reported revenue of HK$6.5B in FY2025 versus HK$5.4B in FY2021, a compound +4.7%/yr. Reported net income was HK$396M in FY2025, compounding −6.0%/yr from FY2021.
of which total revenue +6.1 pp · buybacks/dilution +0.0 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
Watch 1666: get an alert when its fair value changes →
Peer Group
Drug Manufacturers - General · 75 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - General median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,220 | $389.47 | -68% |
| Johnson & Johnson, JNJ | $260.86 | $169.04 | -35% |
| AbbVie Inc ABBV | $248.76 | $67.72 | -73% |
| Roche Holding 1RO | €392.80 | €240.14 | -39% |
| Merck & Co MRK | €115.42 | €118.21 | +2% |
| Novartis AG NVSN | 2,742 MXN | 1,964 MXN | -28% |
| AstraZeneca PLC AZN | $158.50 | $127.32 | -20% |
| Novo Nordisk A/S NOVOB | kr 296.35 | kr 409.46 | +38% |
| Sanofi SNYN | 770.00 MXN | 1,041 MXN | +35% |
| GSK plc GSKN | 917.00 MXN | 879.08 MXN | -4% |
Compare Tong Ren Tang Technologies Co Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Tong Ren Tang Technologies Co Ltd (1666) overvalued or undervalued?
What is the fair value of 1666?
What is the quality score of 1666?
What is the revenue of Tong Ren Tang Technologies Co Ltd (1666)?
What is the net profit margin of 1666?
Does Tong Ren Tang Technologies Co Ltd pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Tong Ren Tang Technologies Co Ltd and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.